135 related articles for article (PubMed ID: 18566217)
1. Potent synergy of dual antitumor peptides for growth suppression of human glioblastoma cell lines.
Kondo E; Tanaka T; Miyake T; Ichikawa T; Hirai M; Adachi M; Yoshikawa K; Ichimura K; Ohara N; Moriwaki A; Date I; Ueda R; Yoshino T
Mol Cancer Ther; 2008 Jun; 7(6):1461-71. PubMed ID: 18566217
[TBL] [Abstract][Full Text] [Related]
2. A new molecular targeted therapeutic approach for renal cell carcinoma with a p16 functional peptide using a novel transporter system.
Zennami K; Yoshikawa K; Kondo E; Nakamura K; Upsilonamada Y; De Velasco MA; Tanaka M; Uemura H; Shimazui T; Akaza H; Saga S; Ueda R; Honda N
Oncol Rep; 2011 Aug; 26(2):327-33. PubMed ID: 21567093
[TBL] [Abstract][Full Text] [Related]
3. Peptide-based tumor inhibitor encoding mitochondrial p14(ARF) is highly efficacious to diverse tumors.
Saito K; Iioka H; Kojima C; Ogawa M; Kondo E
Cancer Sci; 2016 Sep; 107(9):1290-301. PubMed ID: 27317619
[TBL] [Abstract][Full Text] [Related]
4. Resistance of primary cultured mouse hepatic tumor cells to cellular senescence despite expression of p16(Ink4a), p19(Arf), p53, and p21(Waf1/Cip1).
Obata M; Imamura E; Yoshida Y; Goto J; Kishibe K; Yasuda A; Ogawa K
Mol Carcinog; 2001 Sep; 32(1):9-18. PubMed ID: 11568971
[TBL] [Abstract][Full Text] [Related]
5. Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.
Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T
Clin Cancer Res; 2003 Oct; 9(13):4884-90. PubMed ID: 14581362
[TBL] [Abstract][Full Text] [Related]
6. Profiles of the 2 INK4a gene products, p16 and p14ARF, in human reference urothelium and bladder carcinomas, according to pRb and p53 protein status.
Le Frère-Belda MA; Gil Diez de Medina S; Daher A; Martin N; Albaud B; Heudes D; Abbou CC; Thiery JP; Zafrani ES; Radvanyi F; Chopin D
Hum Pathol; 2004 Jul; 35(7):817-24. PubMed ID: 15257544
[TBL] [Abstract][Full Text] [Related]
7. INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene.
Pinyol M; Hernández L; Martínez A; Cobo F; Hernández S; Beà S; López-Guillermo A; Nayach I; Palacín A; Nadal A; Fernández PL; Montserrat E; Cardesa A; Campo E
Am J Pathol; 2000 Jun; 156(6):1987-96. PubMed ID: 10854221
[TBL] [Abstract][Full Text] [Related]
8. Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis.
Kanellou P; Zaravinos A; Zioga M; Stratigos A; Baritaki S; Soufla G; Zoras O; Spandidos DA
Cancer Lett; 2008 Jun; 264(1):145-61. PubMed ID: 18331779
[TBL] [Abstract][Full Text] [Related]
9. Alterations in the INK4a/ARF locus and their effects on the growth of human osteosarcoma cell lines.
Park YB; Park MJ; Kimura K; Shimizu K; Lee SH; Yokota J
Cancer Genet Cytogenet; 2002 Mar; 133(2):105-11. PubMed ID: 11943335
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of senescence markers p14(ARF) and p16(INK4a) in breast cancer is associated with an increased risk of disease recurrence and poor survival outcome.
Pare R; Shin JS; Lee CS
Histopathology; 2016 Sep; 69(3):479-91. PubMed ID: 26843058
[TBL] [Abstract][Full Text] [Related]
11. Aberrations of the p14(ARF) and p16(INK4a) genes in renal cell carcinomas.
Kawada Y; Nakamura M; Ishida E; Shimada K; Oosterwijk E; Uemura H; Hirao Y; Chul KS; Konishi N
Jpn J Cancer Res; 2001 Dec; 92(12):1293-9. PubMed ID: 11749694
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of p14ARF, p15INK4b, and p16INK4a inactivation in malignant peripheral nerve sheath tumors.
Endo M; Kobayashi C; Setsu N; Takahashi Y; Kohashi K; Yamamoto H; Tamiya S; Matsuda S; Iwamoto Y; Tsuneyoshi M; Oda Y
Clin Cancer Res; 2011 Jun; 17(11):3771-82. PubMed ID: 21262917
[TBL] [Abstract][Full Text] [Related]
13. Correlation between p14(ARF)/p16(INK4A) expression and HPV infection in uterine cervical cancer.
Kanao H; Enomoto T; Ueda Y; Fujita M; Nakashima R; Ueno Y; Miyatake T; Yoshizaki T; Buzard GS; Kimura T; Yoshino K; Murata Y
Cancer Lett; 2004 Sep; 213(1):31-7. PubMed ID: 15312681
[TBL] [Abstract][Full Text] [Related]
14. Quantitative real-time PCR does not show selective targeting of p14(ARF) but concomitant inactivation of both p16(INK4A) and p14(ARF) in 105 human primary gliomas.
Labuhn M; Jones G; Speel EJ; Maier D; Zweifel C; Gratzl O; Van Meir EG; Hegi ME; Merlo A
Oncogene; 2001 Mar; 20(9):1103-9. PubMed ID: 11314047
[TBL] [Abstract][Full Text] [Related]
15. Possible associations among expression of p14(ARF), p16(INK4a), p21(WAF1/CIP1), p27(KIP1), and p53 accumulation and the balance of apoptosis and cell proliferation in ovarian carcinomas.
Saegusa M; Machida B D; Okayasu I
Cancer; 2001 Sep; 92(5):1177-89. PubMed ID: 11571731
[TBL] [Abstract][Full Text] [Related]
16. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas.
Tannapfel A; Busse C; Weinans L; Benicke M; Katalinic A; Geissler F; Hauss J; Wittekind C
Oncogene; 2001 Oct; 20(48):7104-9. PubMed ID: 11704835
[TBL] [Abstract][Full Text] [Related]
17. Frequent alterations of the p14(ARF) and p16(INK4a) genes in primary central nervous system lymphomas.
Nakamura M; Sakaki T; Hashimoto H; Nakase H; Ishida E; Shimada K; Konishi N
Cancer Res; 2001 Sep; 61(17):6335-9. PubMed ID: 11522621
[TBL] [Abstract][Full Text] [Related]
18. Genetic alterations of INK4alpha/ARF locus and p53 in human hepatocellular carcinoma.
Peng CY; Chen TC; Hung SP; Chen MF; Yeh CT; Tsai SL; Chu CM; Liaw YF
Anticancer Res; 2002; 22(2B):1265-71. PubMed ID: 12168936
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines.
Caca K; Feisthammel J; Klee K; Tannapfel A; Witzigmann H; Wittekind C; Mössner J; Berr F
Int J Cancer; 2002 Feb; 97(4):481-8. PubMed ID: 11802210
[TBL] [Abstract][Full Text] [Related]
20. p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer.
Kawamoto K; Enokida H; Gotanda T; Kubo H; Nishiyama K; Kawahara M; Nakagawa M
Biochem Biophys Res Commun; 2006 Jan; 339(3):790-6. PubMed ID: 16316628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
